Laboratory News and Research

RSS

Signaling molecules have different effects on key inhibitory protein

Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.

22 Sep 2009

Bacterium responsible for outbreaks identified

University of Central Florida Microbiology Professor Keith Ireton has uncovered a previously unknown mechanism that plays an important role in the spread of a deadly food-borne bacterium.

22 Sep 2009

Massachusetts College of Pharmacy and Health Sciences launches new academic center

Massachusetts College of Pharmacy and Health Sciences today officially opened a new 30,000 square foot, $10M academic center at 40 Foster St. in downtown Worcester. On hand at the event were Congressman Jim McGovern (D-MA), Worcester City Manager Michael O’Brien, Worcester Mayor Konstantina Lukes and MCPHS President Charles F. Monahan Jr.

21 Sep 2009

More on Massachusetts' reform lessons

The Minneapolis Star Tribune reports: "Massachusetts is the only state that has adopted the core elements of the plan outlined by President Obama and congressional Democrats: an individual mandate; an employer mandate; subsidies for the poor; insurance market reforms; and an 'exchange,' under which consumers can shop for coverage."

21 Sep 2009

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

New data on signalling proteins, called G proteins, may prove important in fighting diseases such as cardiovascular, neurodegenerative disorders, and cancer. For many decades scientists have puzzled on "How signalling proteins transport and organize in specific areas of the cell?" Researchers from Nano-Science Center and Department of Neuroscience and Pharmacology at the University of Copenhagen provide yet unrecognized clues to solve this mystery.

21 Sep 2009

Manhattan Scientifics inks exclusive licensing contract with Carpenter Technology

Manhattan Scientifics, Inc. (OTCBB: MHTX) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis.

21 Sep 2009

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to enhance and support the scalable manufacturing and growth of human embryonic stem cells (hESCs).

21 Sep 2009

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Three German laboratories utilize Bruker’s molecular identification solution

At the 61st Annual Meeting of the German Society for Hygiene and Microbiology on September 20-23, 2009 in Goettingen, Bruker Daltonics announces that three major German private clinical microbiology laboratories have extended their accreditation according to DIN EN ISO 15189 to include the use of Bruker’s MALDI Biotyper molecular identification solution.

21 Sep 2009

Identification of nitric oxide using lasers and sensors

Nitric oxide, a gas well known to scientists for its myriad functions, has proven challenging to measure accurately outside the laboratory. A team of Princeton and Rice University researchers has demonstrated a new method of identifying the gas using lasers and sensors that are inexpensive, compact and highly sensitive. Such a portable device, suitable for large-scale deployment, could be of great value to atmospheric science, pollution control, biology and medicine.

21 Sep 2009

AFib ablated using visually-guided laser balloon catheter

Physicians at The Mount Sinai Medical Center in New York became the first in the U.S. to ablate atrial fibrillation using a visually-guided laser balloon catheter.

21 Sep 2009

Research combining magnetism and nanotechnology

Researchers led by Daniel Kohane, MD, PhD of Children's Hospital Boston, funded by the National Institutes of Health, have devised a solution that combines magnetism with nanotechnology.

21 Sep 2009

Conference to focus on the impact of healthcare proposals on diagnostic testing

Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute ’09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington, Virginia.

19 Sep 2009

New head appointed at NeuroFocus' neurological testing laboratory facility

...

19 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Laboratory News and Research

Signaling molecules have different effects on key inhibitory protein

Bacterium responsible for outbreaks identified

Massachusetts College of Pharmacy and Health Sciences launches new academic center

More on Massachusetts' reform lessons

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

Manhattan Scientifics inks exclusive licensing contract with Carpenter Technology

MDC scientist receives 1 million euros for diabetic research

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Clinical trial results of topical INCB18424 inhibitor announced by Incyte Corporation

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

FDA approves Neuralstem's IND for commencing a stem cell trial to treat Amyotrophic Lateral Sclerosis

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Three German laboratories utilize Bruker’s molecular identification solution

Identification of nitric oxide using lasers and sensors

AFib ablated using visually-guided laser balloon catheter

Research combining magnetism and nanotechnology

Conference to focus on the impact of healthcare proposals on diagnostic testing

New head appointed at NeuroFocus' neurological testing laboratory facility

Research program to study personalized medicine

A guide to density measurement excellence eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo